Please ensure Javascript is enabled for purposes of website accessibility

FDA Authorizes New 5 Minute Test to Accelerate U.S. Coronavirus Response

By Cory Renauer - Updated Apr 6, 2020 at 9:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA has allowed a COVID-19 test to be used that can provide results while patients wait.

Rapid testing for the novel coronavirus that's responsible for at least 100,000 cases of COVID-19 in the U.S. is getting an important upgrade. Abbott (ABT 1.79%) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes.    

The fastest test yet

Abbott isn't the first company in the U.S. to launch a point-of-care coronavirus test, but the Abbott ID NOW COVID-19 test is much quicker than the competition. On March 22, Danaher (DHR 1.07%) received a EUA for a test that can provide a result in about 45 minutes.

COVID-19 test blood sample

Image source: Getty Images.

This is Abbott's second EUA for a COVID-19 test this month. About a week ago, the FDA green-lighted a test that runs on systems generally limited to laboratories and hospitals.

Ramping up

According to Abbott, more ID NOW machines are available to run its new COVID-19 test than any other point-of-care molecular diagnostic platform. Since its launch in 2014, the toaster-size nucleic acid amplification machine has become popular in doctor's offices and urgent care centers across the U.S.

The ID NOW platform is already the most common method that American healthcare providers use to check patients for influenza and respiratory syncytial virus, which means Abbott should be able to dramatically ramp up test availability. For both platforms combined, the company expects to produce around 5 million tests per month.

Next week, Abbott will begin making ID NOW COVID-19 tests available to urgent care centers in an attempt to create the greatest immediate impact, with wider distribution to follow.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$109.84 (1.79%) $1.93
Danaher Corporation Stock Quote
Danaher Corporation
DHR
$288.30 (1.07%) $3.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.